Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.

× No keyword cloud information.

14 in total

1. Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.

Authors: Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharsky; Nicole Chan; Hasan Uludağ
Journal: Pharm Res Date: 2015-07-01 Impact factor: 4.200

Review 2. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Authors: Paul L McCormack; Susan J Keam
Journal: Drugs Date: 2011-09-10 Impact factor: 9.546

3. Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).

Authors: Ajoy K Samanta; Sandip N Chakraborty; Yan Wang; Ellen Schlette; E Premkumar Reddy; Ralph B Arlinghaus
Journal: Genes Cancer Date: 2010-04

4. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.

Authors: Dan Jones; Suzanne Kamel-Reid; David Bahler; Henry Dong; Kojo Elenitoba-Johnson; Richard Press; Neil Quigley; Paul Rothberg; Dan Sabath; David Viswanatha; Karen Weck; James Zehnder
Journal: J Mol Diagn Date: 2008-12-18 Impact factor: 5.568

5. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors: C Walz; N C P Cross; R A Van Etten; A Reiter
Journal: Leukemia Date: 2008-06-05 Impact factor: 11.528

Review 6. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

Authors: Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal: Clin Lymphoma Myeloma Leuk Date: 2013-07-26

Review 7. Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Authors: Simona Soverini; Caterina De Benedittis; Manuela Mancini; Giovanni Martinelli
Journal: Oncologist Date: 2016-03-31

8. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

Authors: Simona Soverini; Gianantonio Rosti; Ilaria Iacobucci; Michele Baccarani; Giovanni Martinelli
Journal: Oncologist Date: 2011-05-31

9. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

Authors: Cristian Bellodi; Maria Rosa Lidonnici; Ashley Hamilton; G Vignir Helgason; Angela Rachele Soliera; Mattia Ronchetti; Sara Galavotti; Kenneth W Young; Tommaso Selmi; Rinat Yacobi; Richard A Van Etten; Nick Donato; Ann Hunter; David Dinsdale; Elena Tirrò; Paolo Vigneri; Pierluigi Nicotera; Martin J Dyer; Tessa Holyoake; Paolo Salomoni; Bruno Calabretta
Journal: J Clin Invest Date: 2009-04-13 Impact factor: 14.808

10. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Authors: Timothy Hughes; Giuseppe Saglio; Susan Branford; Simona Soverini; Dong-Wook Kim; Martin C Müller; Giovanni Martinelli; Jorge Cortes; Lan Beppu; Enrico Gottardi; Dongho Kim; Philipp Erben; Yaping Shou; Ariful Haque; Neil Gallagher; Jerald Radich; Andreas Hochhaus
Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544